Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer

International Journal of Cancer

Volumn 131, Issue 1, 2012, Pages 253-263

  Kangasniemi, Lotta ^a,b,c   Parviainen, Suvi ^a,b   Pisto, Tommi ^a,b   Koskinen, Mika ^d   Jokinen, Mika ^d   Kiviluoto, Tuula ^b   Cerullo, Vincenzo ^a,b   Jalonen, Harry ^d   Koski, Anniina ^a,b   Kangasniemi, Anna ^a,b   Kanerva, Anna ^a,b   Pesonen, Sari ^a,b   Hemminki, Akseli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Oncos Therapeutics   (Finland)

^d DelSiTeCh Ltd   (Finland)

Author keywords

gene therapy; oncolytic virus; pancreatic cancer

Indexed keywords

CAPSID MODIFIED ONCOLYTIC ADENOVIRUS; CYTOKINE; GEMCITABINE; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS; SILICA GEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL KILLING; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE MODEL; DRUG EFFECT; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SYRIAN HAMSTER; TISSUE PREPARATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, NEUTRALIZING; CAPSID; CAPSID PROTEINS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CRICETINAE; DEOXYCYTIDINE; FEMALE; HUMANS; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; SILICA GEL; TRANSFECTION;

EID: 84860217802     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26370     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB,. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211-8.
3. Nettelbeck DM,. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J Mol Med 2008; 86: 363-77.
4. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT,. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-13.
5. Cripe TP, Dunphy EJ, Holub AD, Saini A, Vasi NH, Mahller YY, Collins MH, Snyder JD, Krasnykh V, Curiel DT, Wickham TJ, DeGregori J, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus- adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001; 61: 2953-60.
6. Glasgow JN, Everts M, Curiel DT,. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006; 13: 830-44.
7. Grzesiak JJ, Ho JC, Moossa AR, Bouvet M,. The integrin-extracellular matrix axis in pancreatic cancer. Pancreas 2007; 35: 293-301.
8. Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, Han T, Curiel DT,. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 2002; 13: 1647-53.
9. Yotnda P, Zompeta C, Heslop HE, Andreeff M, Brenner MK, Marini F,. Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther 2004; 15: 1229-42.
10. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD, Korc M,. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 1998; 102: 1662-73.
11. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT,. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-80.
12. Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T, Koyuncu D, Drescher MR, Strauss R, Zhang XB, Wahl JK, III, Urban N, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 2011; 17: 96-104.
13. Ramirez PJ, Vickers SM, Ono HA, Davydova J, Takayama K, Thompson TC, Curiel DT, Bland KI, Yamamoto M,. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am J Surg 2008; 195: 481-90.
14. Kangasniemi L, Kiviluoto T, Kanerva A, Raki M, Ranki T, Sarkioja M, Wu H, Marini F, Hockerstedt K, Isoniemi H, Alfthan H, Stenman UH, et al. Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin Cancer Res 2006; 12: 3137-44.
15. Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A,. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 2005; 12: 1198-205.
16. Guse K, Ranki T, Ala-Opas M, Bono P, Sarkioja M, Rajecki M, Kanerva A, Hakkarainen T, Hemminki A,. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol Cancer Ther 2007; 6: 2728-36.
17. Sarkioja M, Kanerva A, Salo J, Kangasniemi L, Eriksson M, Raki M, Ranki T, Hakkarainen T, Hemminki A,. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer 2006; 107: 1578-88.
18. Ranki T, Sarkioja M, Hakkarainen T, von Smitten K, Kanerva A, Hemminki A,. Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int J Cancer 2007; 121: 165-74.
19. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-30.
20. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP,. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
21. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D,. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-9.
22. Yu W, Fang H,. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007; 7: 141-8.
23. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML,. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
24. Quintanar-Guerrero D, Ganem-Quintanar A, Nava-Arzaluz MG, Pinon-Segundo E,. Silica xerogels as pharmaceutical drug carriers. Expert Opin Drug Deliv 2009; 6: 485-98.
25. Czarnobaj K, Lukasiak J,. In vitro release of cisplatin from sol-gel processed porous silica xerogels. Drug Deliv 2004; 11: 341-4.
26. Prokopowicz M,. In-vitro controlled release of doxorubicin from silica xerogels. J Pharm Pharmacol 2007; 59: 1365-73.
27. Kangasniemi L, Koskinen M, Jokinen M, Toriseva M, Ala-Aho R, Kahari VM, Jalonen H, Yla-Herttuala S, Moilanen H, Stenman UH, Diaconu I, Kanerva A, et al. Extended release of adenovirus from silica implants in vitro and in vivo. Gene Ther 2009; 16: 103-10.
28. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449-58.
29. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R,. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120-6.
30. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18: 1874-84.
31. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WS,. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-6.
32. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Sarkioja M, Rajecki M, Kangasniemi L, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010; 70: 4297-309.
33. Cohen AM, Hines DK, Korach ES, Ratzkin BJ,. In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor. Infect Immun 1988; 56: 2861-5.
34. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 18: 1874-84.
35. Guse K, Dias JD, Bauerschmitz GJ, Hakkarainen T, Aavik E, Ranki T, Pisto T, Sarkioja M, Desmond RA, Kanerva A, Hemminki A,. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. Gene Ther 2007; 14: 902-11.
36. Rajecki M, Kanerva A, Stenman UH, Tenhunen M, Kangasniemi L, Sarkioja M, Ala-Opas MY, Alfthan H, Sankila A, Rintala E, Desmond RA, Hakkarainen T, et al. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol Cancer Ther 2007; 6: 742-51.
37. Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, Nettelbeck DM,. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 2004; 11: 1694-702.
38. Pesonen S, Helin H, Nokisalmi P, Escutenaire S, Ribacka C, Sarkioja M, Cerullo V, Guse K, Bauerschmitz G, Laasonen L, Kantola T, Ristimaki A, et al. Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol. 2010; 49: 117-9.
39. Pesonen S, Nokisalmi P, Escutenaire S, Särkioja M, Cerullo V, Laasonen L, Guse K, Haavisto E, Oksanen M, Rajecki M, Ristimäki A, Kantola T, et al. Efficasy, toxicity, correlative and immunological analysis of cancer patients treated with oncolytic adenovirus Ad5/3-Cox2L-D24. Mol Ther 2009; 17: S98.
40. Pan JJ, Zhang SW, Chen CB, Xiao SW, Sun Y, Liu CQ, Su X, Li DM, Xu G, Xu B, Lu YY,. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 799-804.
41. Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN. 1.3.001. J Clin Oncol 2008; 26: 3695-701.
42. Reid T, Warren R, Kirn D,. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2002; 9: 979-86.
43. Muruve DA, Barnes MJ, Stillman IE, Libermann TA,. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-76.
44. Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, Rodgers JR, Lee B,. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 2007; 15: 378-85.
45. Nemunaitis J, Senzer N, Sarmiento S, Zhang YA, Arzaga R, Sands B, Maples P, Tong AW,. A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther 2007; 14: 885-93.
46. Nemunaitis J, Vorhies JS, Pappen B, Senzer N,. 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. Cancer Gene Ther 2007; 14: 762-3.
47. Petry H, Brooks A, Orme A, Wang P, Liu P, Xie J, Kretschmer P, Qian HS, Hermiston TW, Harkins RN,. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther 2008; 15: 54-60.
48. Chen Y, Yu DC, Charlton D, Henderson DR,. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000; 11: 1553-67.
49. Lenaerts L, De Clercq E, Naesens L,. Clinical features and treatment of adenovirus infections. Rev Med Virol 2008; 18: 357-74.
50. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE,. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001; 3: 28-35.